INTRODUCTION
CML
CML, CHROMOSOMAL TRANSLOCATION, CHRONIC MYELOID LEUKEMIA
Chronic myeloid leukemia (CML) is characterized by a chromosomal translocation leading to the generation of the Philadelphia (Ph) chromosome and expression of the Bosutinib is an orally active, dual Src/Abl TKI that displays greater potency against The present analysis integrated data from the BELA, BFORE and B1871048 trials in order to assess quantitatively the impact of reducing the starting dose of bosutinib from 500 to 400 mg QD with respect to the relationships between pharmacokinetic (PK) metrics of bosutinib exposure and key efficacy and safety outcomes in adult patients with newly diagnosed CP‐CML. It also aimed to identify potential covariates that may be important predictors of variability in bosutinib distribution and elimination.